March 6, 2024  SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica, announced that the FDA has granted Breakthrough Device designation to its Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The unique design is the first to use the contrast management mechanism of action, incorporating thousands of elements that gently scatter light across the retina. DOT spectacle lenses are commercially available in several markets, including China, the Netherlands, and Israel.